跳至主要内容
临床试验/NCT04340128
NCT04340128已完成3 期

Evaluation of Efficacy of Intra-lesional Injections of Glucantime Once Weekly in Comparison With Twice Weekly in the Treatment of Acute Anthroponotic Cutaneous Leishmaniasis (ACL)

Tehran University of Medical Sciences1 个研究点 分布在 1 个国家开始时间: 2007年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
试验地点
1
主要终点
Complete healing of the lesion(s)

研究概览

简要总结

Anthroponotic Cutaneous Leishmaniasis (ACL) is a parasitic disease caused by Leishmania tropica, pentavalent antimonials (sodium stibogluconate and meglumine antimoniate) have been used as a standard treatment for leishmaniasis for last 80 years. Systemic antimonial injection is painful, toxic, not affordable and moreover is not always effective. Many different modalities are used to treat the disease with a limited success. Intra-lesional injections of antimonials are used for the treatment of patients with a few lesions but no data is available on the rate of efficacy. In this study the efficacy of intra-lesional injections of Glucantime weekly is compared with intra-lesional injections of Glucantime twice weekly.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single

入排标准

年龄范围
9 Years 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Parasitologically proven cases of CL based on positive smear and/or culture
  • Otherwise healthy subjects on the basis of medical history.
  • Age 9-70 years
  • Willing to participate in the study and sign the informed consent (by the patient or his/her parent/guardian in case of younger than 18 years).

排除标准

  • Pregnant or lactating women
  • Duration of lesion more than 6 months
  • Number of lesions more than 4
  • History of allergy to Glucantime
  • Serious systemic illnesses (as judged by the physician)
  • Participation in any drug trials in the last 60 days
  • No indication for systemic treatment

研究组 & 干预措施

1

Active Comparator

Intra-lesional injection of Glucantime once a week

干预措施: Meglumine antimoniate (Drug)

2

Experimental

Intra-lesional injection twice a week, 0.1/cm2

干预措施: Meglumine antimoniate (Drug)

结局指标

主要结局

Complete healing of the lesion(s)

时间窗: 5 months

次要结局

  • Partiall cure(5 months)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验